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Abstract
BACKGROUND: Carbofuran is a carbamate insecticide that inhibits AChE. Although toxic by ingestion in mammals, it has low
dermal toxicity, with relatively few conﬁrmed worker illnesses. This risk assessment describes its time of onset, time to peak
effect and time to recovery in rats using brain AChE inhibition in acute and 21 day dermal studies; invitro rat/human relative
dermalabsorptionforgranular(5G)andliquid(4F)formulations;occupationalexposureestimatesusingthePesticideHandlers’
Exposure Database andAgricultural Handlers’Exposure Database (PHED/AHED).
RESULTS: The point of departure for acute risk calculation (BMDL10)w a s6 . 7m gk g −1 day−1 for brain AChE inhibition after 6 h
exposure. In a 21 day study, the BMDL10 was 6.8 mgkg−1 day−1, indicating reversibility. At 75 mgkg−1 day−1,t i m eo fo n s e t
was ≤30 min and time to peak effect was 6–12 h. Rat skin had ca tenfold greater dermal absorption of carbofuran (Furadan
5G or 4F) thanhumanskin. Exposureestimatesfor 5G in rice and4F in tencrops hadadequatemargins of exposure (>100).
CONCLUSION: Rat dermal carbofuran toxicity was assessed in terms of dose and time-related inhibition of AChE. Comparative
dermal absorption in rats was greater than in humans. Worker exposure estimates indicated acceptable risk for granular and
liquidformulationsof carbofuran.
c   2011 Societyof Chemical Industry
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1I N T R O D U C T I O N
Carbofuran is an N-methyl-carbamate insecticide/nematicide
that has been used worldwide for about 40 years. It is systemic
in plants and has a wide variety of crop uses, being effective
in the control of both soil-dwelling and leaf-eating insects. Like
the organophosphate insecticides, carbamates are inhibitors of
acetylcholinesterase (AChE) and have high acute oral toxicity
to mammals. However, unlike organophosphates, carbamates
reversibly inhibit AChE1–3 and have considerably lower dermal
toxicity,1 giving them a lower propensity to cause worker
exposure illnesses, where the principal route of exposure is
dermal. Occasional cases of worker illness have typically resulted
from lack of adherence to label directions.4
Carbofuran technical is classiﬁed by the World Health
Organization as highly hazardous, category 1b (rat oral LD50
5–50mgkg−1).However,thisclassiﬁcationbeliesthefactthatthe
technical product has a better safety proﬁle by the dermal route
(LD50 of >1000 mg kg−1 in rat and >2000 mg kg−1 in rabbit1)
and would be classiﬁed as category II or III under WHO guidelines
(moderatelyorslightlyhazardous).Asmuchassuchclassiﬁcations
are helpful in standardizing comparisons of technical product,
they are less relevant to actual agricultural settings. Growers are
exposedto formulationsandnottechnical product, andtherefore
the toxicity of the end-use formulation tends to be more relevant
as a basis for establishing appropriate warnings to users. Granular
carbofuran, containing 3 or 5% of the active ingredient, has much
less toxicity than carbofuran technical via the dermal or oral
routes. Toxicity by the inhalation route is largely dependent on
the friability or dustiness of the granule, dusty granules having
a greater likelihood of manifesting toxicity by inhalation. Thus,
it is important for manufacturers and regulatory agencies to set
a standard for low dust in the interest of worker safety and for
responsible manufacturers to adhere to these standards.
Worker exposure risk assessments typically involve the calcula-
tionofamarginofexposure(MOE)bydividingatoxicologicalpoint
of departure (POD), such as a no-observed-effect level (NOEL) or
benchmark dose (BMD), by an exposure estimate. An MOE above
100 is generally considered to be adequate to protect a person
fromthetoxiceffectsofapesticidewheneverthePODisbasedon
an animal experiment. Key aspects such as time of onset, time to
peak effect and time to recovery contribute to an understanding
ofthetoxicodynamicsofacarbamateinsecticide.Also,acompara-
tiverat/humandermalpenetrationstudycancontributetoamore
accurate extrapolation from the test animal to humans.
Thispaperdescribestheresultsofstudiesonthedermaltoxicity
of carbofuran and the relevance of those results to worker risk for
both granular and liquid formulations. A 21 day dermal study and
acute studies of time to peak effect, onset of effect and reversibil-
ity, as well as skin absorption, are reported for two formulations
(Furadan 5G and Furadan 4F). Occupational exposure was es-
timated using the Pesticide Handlers’ Exposure Database (PHED)5
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and the Agricultural Handlers’ Exposure Database (AHED),6 stan-
dard databases in the United States. The results were then
subjected to a worker risk analysis, the results of which shed light
onthesafetyofcarbofuranuseasaliquidandgranularformulation.
2 MATERIALSAND METHODS
During 2009, three acute studies and one 21 day study were
conducted at WIL Research Laboratories, Ashland, Ohio,7–10in an
attempt better to deﬁne the toxicology of carbofuran in the rat
after dermal exposure. Groups of rats (10 sex−1 time interval−1)
were exposed for speciﬁc times to carbofuran technical, applied
as an aqueous paste, followed by washing of the treatment site
for the removal of carbofuran residue. Initially, a dose response
was developed for brain and red blood cell (RBC) AChE inhibition
followinga6 hdermalexposure.7 Because6 hwaswithinthetime
period for maximum brain AChE inhibition, the above study was
used to determine a BMDL10 for brain AChE inhibition that was
consideredto be suitable forrisk assessment. Adose was selected
(75 mg kg−1 day−1) that consistently gave ≥20% inhibition of
RBC and brain AChE in both sexes for two follow-up studies
that examined the time course of inhibition. In the time-of-
o n s e ts t u d y ,g r o u p so fr a t s( 1 0s e x −1 time−1) were exposed to
75 mg kg−1 day−1 for 0.5, 1.5, 3.0 and 6.0 h, followed by skin
washingforremovalofcarbofuranresidue,withadditionalgroups
assayed at 24 h after the 6.0 h exposure.8
Time to peak effect and time to recovery were studied using
groups of rats dosed dermally at 75 mg kg−1 day−1 for 6 h,
followed by skin washing.9 Then, AChE activity was measured
at 6, 7.5, 9, 12, 24, 48 and 72 h after initial exposure. Recovery of
AChE activity after acute exposure was slower than expected, so a
21 day study was conducted, with double washing of each rat at
the end of each day’s exposure period (6 h).10
In order to better translate to humans, relative dermal
absorption of carbofuran was assessed using carbofuran with rat
and human skin tissue invitro. Finally, potential worker exposure
was estimated, using PHED5 and AHED6 computer models and
subsequent risk-assessment-derived MOEs for typical uses of
carbofuran, following dermal exposure.
Allstudiesinthisserieswereconductedaccordingtothecurrent
USEPAFIFRA GLP standards.
2.1 Assessmentofthedermaltoxicityofcarbofurantechnical
in therat7–10
At WIL Research Laboratories LLC, Ashland, Ohio, carbofuran
technical (98.4% purity) was administered to the shaved skin of
adult rats of both sexes as a paste, mixed with deionized water
justpriortoapplication.Basedonthebodyweightofeachrat,the
appropriateamountofcarbofuranwasweighedintoaweigh-boat
sothateachratwouldgetthespeciﬁeddosageinmg kg−1 day−1.
In the ﬁrst acute dermal study, rats were exposed to carbofuran
for 6 h at 0, 25, 75, 150 and 250 mg kg−1. The time-course studies
wereconductedat75 mg kg−1 day−1,theLOELinbothsexesfrom
theinitialacutestudy.Ina21 daydermalstudy,ratsweredosedat
0,20,50and100 mg kg−1 day−1.Groupsofrats(10sex −1 dose−1)
were administered an aqueous paste of carbofuran to the clipped
dorsum for 6 h, in the same way as for the acute dermal studies,
and the process was repeated daily on days 0 to 20.
Animals used were ca eight-week-old Crl:CD(SD) rats from
Charles River Laboratories, Inc., Raleigh, North Carolina. The rats
were acclimated for 2 weeks at WIL Laboratories, Inc. Body
weights at the start of dosing were 219–310 g (males) and
164–230 g (females). Areas of skin were clipped from the back
of each rat on the day prior to dosing, such that the area dosed
with carbofuran was ca 10% of the body surface area. Control
groups were administered ca 3–4 mL of vehicle (water). After
the dosing of each rat, the application site was covered with
a porous gauze wrap around the trunk, secured with elastic
Co-Flex bandage and held in place with non-irritating tape.
Elizabethan collars were placed on all rats following dosing to
prevent oral ingestion. At the end of each treatment period
(usually 6 h), dressings and collars were removed, and the test
sites were gently washed (distilled water, 1% baby shampoo,
distilled water) using moist disposable paper towels, followed
by drying with dry towels. In order to remove the carbofuran
residue from the skin surface more completely, the washing
process for the rat skin was repeated twice (compared with the
acute studies) after each daily 6 h exposure for the 21 day study.
Collars were replaced on animals except for those that were
euthanized(carbondioxide)forAChEdeterminationatscheduled
time points.
At scheduled time points (see Section 2), rats were dissected
for collection of blood (ca 1 mL, vena cava), in heparinized test
tubes,andbrain,in1%Triton X-100.Allsamplesweremaintained
on ice until further processing to ensure minimal reactivation of
AChE. Measurement of cholinesterase activity started within 1 h
of sample collection, a period that was found to avoid signiﬁcant
reactivation of AChE in a previous validation experiment using
another carbamate, propoxur.7–10 RBC and whole-brain AChE
activity were measured by a modiﬁed Ellman reaction,11,12 using
acetylthiocholine as a substrate.
The BMDL10 for AChE inhibition was calculated using USEPA’s
benchmark dose software (BMDS 2.1.2), in place of a NOEL. The
Hill model consistently gave the best ﬁt of data and was used for
the BMD calculations.
2.1.1 Dermal absorption study of carbofuran in Furadan 5G (5%)
usinghumanandratskininvitro13
A dermal absorption/penetration study was conducted by ADME,
Vergese, France.13 Dermatomed human skin samples (mean
thickness 247 ± 80 µm) were obtained from the abdomen of
two female Caucasians, aged 31 and 48, and stored at −20
◦C. Rat
skinsamples(meanthickness379±15.5 µm)wereobtainedfrom
two male hairless rats, aged 7 weeks, and stored at −20
◦C. Two
skin samples were tested from each subject. Skin samples were
mounted in a chamber bathed in static receptor ﬂuid containing
NaCl (9 g L−1)a n dP B Sb u f f e r( 9 . 6gL −1), plus water containing
5% acetone, at pH 6.5–7.0. A ﬂowing water jacket maintained
the temperature at 32 ± 1
◦C. Skin integrity was assessed by
measuring water loss from the stratum corneum,a n dt h i sw a s
found to be within acceptable limits. Carbofuran was quantiﬁed
usingavalidatedGC/MSmethod.Dosingusedcrushed5Ggranules
containing6.2%carbofuran(measured)atalevelofca10mg cm−2,
without dilution.
The skin chamber was humidiﬁed with water before dosing
so as to mimic the presence of sweat. The receptor ﬂuid was
sampled on six occasions within the 24 h study duration, and
carbofuran was measured. The granules were left on the skin for
8 hbeforewashingwithhumidiﬁedcotton,waterandTween 80.
The amount of carbofuran was measured at 24 h in samples of
receptor ﬂuid, epidermis plus dermis, stratum corneum and skin
excess, and recovery was recorded.
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2.1.2 Dermal absorption study using human and rat skin invitro
with[14C]-carbofuraninFuradan 4F14 (4lbUSgallon−1)
Another carbofuran dermal absorption/penetration study was
conducted by Stratacor Inc., Richmond, California.14 Freshly
excised human skin samples (n = 18) were obtained from
the Cooperative Human Tissue Network (NIH, CHTN, Vanderbilt
UniversityMedicalCenter,Nashville,Tennessee)anddermatomed
to250–500 µm thickness(sixsamplesfromeach ofthreedonors).
Similar samples of rat skin were also obtained (250–350 µm). An
area of ca 0.8 cm2 of skin was exposed to treatment. Each skin
samplewasmountedintoachamberwiththevisceralsidebathed
in ﬂowing receptor ﬂuid containing tissue culture medium (RPMI
formula1640)plusNaHCO3,Hepesbuffer,4%BSAandgentamicin
(50 mg L−1). Prior to each experiment, the integrity of each skin
preparation was tested by applying [3H]-water; if the receptor
ﬂuid contained more than 3000 dpm after 1 h of incubation, the
skin sample was assumed to be damaged and was discarded.
[14C]-Carbofuran (Furadan 4F) was phenyl UL at a speciﬁc
activity of 55.4 mCi mmol−1, with a purity of 96.9%, and [14C]-
piperonyl butoxide, also phenyl UL labeled, had a speciﬁc activity
of 36.5 mCimmol−1 and a purity of 96.5%. Dosing was conducted
toachieveachemicaldoseofca5900µgc m −2 ofcarbofuran(both
concentrated and dilute solutions) or 100 µgc m −2 of piperonyl
butoxide, with a [14C] dose of ca 2220000 DPMcm−2.
[14C]-Carbofuran or positive control ([14C]-piperonyl butoxide)
was applied at ca 10 mg 0.8 cm−2, and samples of receptor ﬂuid
were taken at intervals over 24 h. After 8 h, the clamp and donor
chamberwereremovedfromtheskinsurface,andexcessmaterial
was removed from the skin surface using soap, water and dry
wipes.Followingdecontamination,thedonorchamberandclamp
were repositioned on the skin surface. At 24 h after application,
the clamp and donor chamber were again removed from the skin
surface, and human skin was then tape stripped (twice) and the
epidermisanddermiswereseparated.Forratskin,tapestripswere
not used, as this process had been found to damage rat skin. For
humanandratskin,aconservativeestimateofskinabsorptionwas
obtained by adding the total [14C] in the skin (epidermis, dermis
and tape strips for human skin) to that found in the receptor
ﬂuid.Becauseoflikelylossofepidermisresiduesthroughwashing
invivo,alessconservativecalculationcombinedthe[14C]residues
found in dermis with that in receptor ﬂuid.
2.2 Occupational exposure estimationscenarios
2.2.1 Occupationalexposureforgranulestorice
TheestimationofoccupationalexposureusedPHEDforFuradan
3G. The major application scenarios for workers applying the
product were as follows:
• mixing/loading and application of granular: ‘push-type’ gran-
ular spreader (open pour) on rice;
• mixing/loading of granular: open mixing/loading for solid
broadcast spreader application on rice;
• applicationofgranular:solidbroadcastspreader,opencab,on
rice.
Theoccupationalexposureassessmentswerebasedonbaseline
personal protective equipment (PPE) as follows:
• mixing/loadingofgranular:anopenmixingandloadingsystem
needs minimum PPE – a single layer, no gloves or respirator;
• solid broadcast spreader: an open cab with a single layer, no
gloves or respirators.
2.2.2 Occupationalexposureforliquidtovegetablesandrowcrops
Theestimationofoccupationalexposure(mixer/loader/applicator:
M/L/A) used AHED and PHED for Furadan 4F. The major
application scenarios for workers applying the liquid product
were as follows:
• mixing/loading and application of liquids: aerial/groundboom
canola, mustard, corn;
• mixing/loading and application of liquids: groundboom sun-
ﬂower,greenpepper,potato,sugarbeet,strawberry,raspberry,
rutabaga, turnip.
Theoccupationalexposureassessmentswerebasedondifferent
levels of personal protective equipment (PPE) as follows:
• mixing/loading of liquids: an open mixing and loading system
needs maximum PPE – chemical-resistant coveralls over a
single layer, chemical-resistant gloves and respirator;
• groundboomapplication: aclosedcab withchemical-resistant
coveralls over a single layer, no gloves or respirators;
• aerial application: a single layer (long-sleeved shirt and long
trousers), with no gloves or respirators.
2.3 Calculationsfor daily amountexposed
The values of ‘daily area treated’ for each application method,
based on USEPA’s Health Effects Division’s Science Advisory
Council for Exposure, policy number 9 of ‘Standard values for
daily acres treated in agriculture’, were the same as those used in
Canada by the Pest Management Regulatory Agency (PMRA).
2.4 Calculationsfor occupational exposure
The PHED5 scenario used for Furadan 3G was ‘open mix-
ing/loading of granular’, ‘open cab solid broadcast spreader
application’, ‘push-type granular spreader mixing/loading and
application’. For Furadan 4F, ‘enclosed cab aerial application of
liquidformulations’andtwoAHED6 scenariosof‘openpourmixing
and loading of liquid formulations’ and ‘open cab groundboom
application of liquid sprays’ were used. In the scenario of ‘closed
cab groundboom application of liquids’, because AHED does
not have this speciﬁc scenario, a protection factor of 90% was ap-
pliedforextrapolationfrom‘opencabgroundboomapplication’to
‘closedcabgroundboomapplication’.The90%protectionfactoris
consideredveryconservative(healthprotective)becauseitresults
in a ﬁvefold higher exposure estimate (10% versus 2%) than the
protection factor of 98% as recommended for the extrapolation
from ‘open cabs’ to ‘enclosed cabs’.6
2.5 Workerriskassessment
The MOEs for the dermal route of exposure were calculated using
the following equation:
MOEdermal =
BMDL10(dermal,µgk g
−1 day
−1)
dermal exposure dosage (µgk g
−1 day
−1)
3R E S U L T S
3.1 Dose selection for acute effects
Groupsoftenratsofeachsexwereexposedtocarbofurandermally
for 6 h at dosages of 0, 25, 75, 150 and 250 mg kg−1 day−1,7 and
AChE activity was measured for RBC and brain (Table 1, Fig. 1).
Both sexes showed dose-dependent inhibition of AChE, with the
wileyonlinelibrary.com/journal/ps c   2011 Society of Chemical Industry PestManagSci 2012; 68: 362–3703
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Table 1. AChE activity (% inhibition) in the rat after dermal exposureto carbofuran (6 h)a
Dose (mg kg−1
day−1) Male RBC Male brain Female RBC Female brain Combined sexesRBC Combine sexesbrain
0 3303 ± 817 47768 ± 2227 3148 ± 553 46768 ± 2756 3226 ± 683 47268 ± 2492
25 2389 ± 454∗ 37826 ± 4444∗∗ 2599 ± 646 37553 ± 3278∗∗ 2494 ± 554 ∗∗ 37689 ± 3803∗∗
(27.7%) (20.8%) (17.5%) (19.7%) (22.7%) (20.3%)
75 2410 ± 912∗ 32391 ± 7908∗∗ 2517 ± 818 36702 ± 4761∗∗ 2464 ± 845∗∗ 34547 ± 6727∗∗
(27.0%) (32.2%) (20.0%) (21.5%) (23.6%) (26.9%)
150 2133 ± 959∗∗ 30199 ± 9543∗∗ 2630 ± 724 32271 ± 6733∗∗ 2382 ± 866∗∗ 31235 ± 8108∗∗
(35.4%) (36.8%) (16.5%) (31.0%) (26.2%) (33.9%)
250 2059 ± 516∗∗ 28523 ± 6685∗∗ 2379 ± 762 31354 ± 7738∗∗ 2219 ± 654∗∗ 29939 ± 7186∗∗
(37.7%) (40.3%) (24.4%) (33.0%) (31.2%) (36.7%)
∗ P < 0.05 different from control.
∗∗ P < 0.01 different from control.
a Mean enzymeactivity U/L ± standard deviation (percentageinhibition compared with control).2
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Figure 1. Inhibition of brain AChE activities following acute dermal
exposureto carbofuran technical for 6 h.2.
exception of RBC AChE inhibition in females, with few clinical
signs. A BMDL10 of 6.7 mg kg−1 day−1 was obtained for brain
AChE inhibition from this study (Fig. 1). Brain AChE was inhibited
by a greater percentage than RBC AChE at three of four dosages
in males and four of four dose levels in females. Therefore, brain
AChE inhibition was considered to be a more reliable indicator of
toxicity than RBC AChE inhibition.
From the dose response it was determined that 75 mg kg−1
day−1 wassuitableforstudyingthetimecourseofAChEinhibition
because it was the lowest dose that caused ≥20% inhibition of
brain and RBC AChE in both sexes at 6 h. This low dosage would
allowabetterassessmentofrecoverythanahigherone.Inhibition
of rat brain AChE of 20% has recently been used by WHO/FAO to
establish an acute RfD for dietary risk assessment of carbofuran.2
3.2 Time toonset andtime topeak effect
In general, the inhibition of both brain and RBC AChE increased
with duration of dermal exposure at 75 mg kg−1 day−1.8 The
inhibition of brain AChE was greater than RBC AChE inhibition
at all ﬁve time points, for both males and females. Male and
femaleratsshowedsimilardegreesofenzymeinhibition(Table 2).
Because AChE was inhibited by 22–33%after 30 min of exposure,
the time of onset for AChE inhibition was 30 min or less. Similarly,
AChE inhibition after 6 h exposure was greater than after 3 h, so
the time to peak effect was probably 6 h or greater.
Table 2. AChE activity (% inhibition) in the rat after dermal exposure(0–6 h) with carbofuran at 75 mg kg−1a
Exposure
duration (h) Male RBC Male brain FemaleRBC Female brain
Combined
sexesRBC
Combinedsexes
brain
0 4314 ± 883 49148 ± 1698 4285 ± 748 48930 ± 2215 4300 ± 797 49039 ± 1924
0.5 3253 ± 656∗ 33983 ± 5890∗ 3304 ± 752∗ 32731 ± 6569∗ 3279 ± 687∗∗ 33357 ± 6106∗∗
(24.6%) (30.9%) (22.9%) (33.1%) (23.7%) (32.0%)
1.5 2811 ± 718∗ 29817 ± 5613∗ 3035 ± 692∗ 31178 ± 7357∗ 2923 ± 696∗∗ 30498 ± 6407∗∗
(34.8%) (39.3%) (29.2%) (36.3%) (32.0%) (37.8%)
3.0 2948 ± 797∗ 32236 ± 6557∗ 2808 ± 603∗ 31149 ± 6289∗ 2878 ± 692∗∗ 31693 ± 6278∗∗
(31.7%) (34.4%) (34.5%) (36.3%) (33.1%) (35.4%)
6.0 2418 ± 771∗ 26094 ± 8434∗ 2579 ± 1120∗ 28846 ± 5513∗ 2499 ± 940∗∗ 27470 ± 7077∗∗
(44.0%) (46.9%) (39.8%) (41.0%) (41.9%) (44.0%)
6.0 + 18 h recovery 3134 ± 973∗ 30172 ± 5369∗ 2893 ± 861∗ 32047 ± 6191∗ 3014 ± 898∗∗ 31110 ± 5721∗∗
(27.4%) (38.6%) (32.5%) (34.5%) (30.1%) (36.6%)
∗ P < 0.05 different from control.
∗∗ P < 0.01 different from control.
a Mean enzymeactivity U/L ± standard deviation (percentageinhibition compared with control).3
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Figure 2. EffectofdermalcarbofuranonratbrainAChEactivity,U/L(mean
± SD).4.
After 6 h of dermal exposure, followed by skin washing and
18 h for potential recovery, partial recovery was observed. The
inhibition of brain AChE had fallen from 41–47% to 35–39%. For
RBCAChE,whichwasmorevariable,similartimeofonsetandtime
to peak effect were observed, along with a similar partial recovery
at 24 h (inhibition 27–33% versus 40–44% at 6 h).
3.3 Time topeak effect andtimetorecovery
Asinpreviousstudies,therewasasubstantialinhibition(25–32%)
ofbrainAChEat6 h.9Becauseofvariability,astatisticallysigniﬁcant
inhibition (P < 0.01) of brain AChE in males and females was
observed only at 12 h. It is likely that the time to peak effect
occurred during the 6–12 h plateau, as there was no signiﬁcant
difference in the brain AChE inhibition recorded at 6, 7.5, 9 and
12 h (Fig. 2). After skin washing at 6 h, a similar degree of brain
AChE inhibition remained at 7.5, 9, 12 and 24 h. Partial recovery
had occurred after 48 and 72 h.
TheinhibitionofRBCAChEwasalsopronouncedat6 h(11–31%)
and formed a plateau until 48 h following dermal exposure. By
72 h, recovery of enzyme activity was essentially complete, as
inhibition was only 7.3% in males or 2.8% in females (Fig. 3). The
inhibition of brain AChE was greater and longer lasting than RBC
AChE inhibition at six of seven time points in males and at ﬁve of
s e v e nt i m ep o i n t si nf e m a l e s .
Thus, following dermal dosing of the rat for 6 h, inhibition of
AChE (brain andRBC) had peakedby 6 h and remaineddepressed
to a similar degree until 12 h and possibly beyond. Because of
Figure 3. Effect of dermal carbofuran on rat RBC AChE activity, U/L (mean
± SD).4.
the plateau of inhibition that occurred following 6 h of dermal
exposure, it is reasonable to consider exposure for 6 h to be
the time to peak effect for conducting reversibility studies. No
signiﬁcant increase in AChE inhibition took place after 6 h, but
recovery from inhibition appeared to be slow. The method of
washing the rat skin was considered to be a confounding factor
for the apparently slow recovery.
3.4 Twenty-oneday dermaldose response
BecauseofthelimitedreversibilityofbrainandRBCAChEinhibition
in the acute dermal studies, it was not clear whether the toxic
effectsofcarbofuranfollowingdermaldosingwouldreversewithin
24 h of the initiation of dosing. Therefore, to assess possible risks
followingrepeateddailyworkerexposure,a21 dayrepeateddose
dermal study was conducted.10 Double washing of the rat skin
(compared with the acute studies) was performed at the end
of each daily 6 h exposure for more complete removal of the
carbofuran residue from the skin surface.
During the 21 day study there were no notable carbofuran-
related clinical signs. Following the ﬁnal 6 h exposure, brain
and RBC AChE activities were measured. AChE inhibition was
signiﬁcant (P < 0.01) in all dose groups in a dose-dependent
manner, but the LOEL for 20% inhibition was between 20 and
50 mg kg−1 day−1 (Table 3). Slightly greater inhibition of RBC
AChE compared with brain AChE was observed. A BMDL10 of
6.8 mg kg−1 day−1 (BMD10 = 9.1m gk g −1 day−1)w a so b t a i n e d
for brain AChE inhibition from this study (Fig. 4). This study
demonstrated that full recovery occurred between daily doses,
astherewasnosigniﬁcantdifferenceintoxicitybetweentheacute
Table 3. AChE activity (% inhibition) in the rat after dermal exposureto carbofuran (21 days)a
Dose
(mg kg−1 day−1) Male RBC Male brain Female RBC Female brain
Combined
sexesRBC
Combined sexes
brain
0 2977 ± 665 50957 ± 2010 2758 ± 780 50495 ± 1686 2868 ± 714 50726 ± 1821
20 2045 ± 352∗∗ 42666 ± 4179∗∗ 2351 ± 1145 40546 ± 3179∗∗ 2198 ± 857∗∗ 41606 ± 3742∗∗
(31.3%) (16.3%) (14.8%) (19.7%) (23.1%) (18.1%)
50 1561 ± 352∗∗ 33580 ± 4867∗∗ 1216 ± 324∗∗ 29652 ± 3662∗∗ 1389 ± 374∗∗ 31616 ± 4676∗∗
(47.6%) (34.1%) (55.9%) (41.3%) (51.6%) (37.5%)
100 1242 ± 326∗∗ 26266 ± 3089∗∗ 832 ± 330∗∗ 24346 ± 5711∗∗ 1037 ± 382∗∗ 25306 ± 4499∗∗
(58.3%) (48.5%) (69.8%) (51.8%) (63.5%) (50.0%)
∗ P < 0.05 different from control.
∗∗ P < 0.01 differentfrom control.
a Mean enzymeactivity U/L ± standard deviation (percentageinhibition compared with control).6
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Figure 4. Inhibition of brain AChE activities after dermal exposure to
carbofuran technicalfor 21 days (6 h day−1).5.
Table 4. Dermal absorption of carbofuran in human and rat skin
exposedto Furadan 5G
Species/doselevel
Human/9.56±
0.48 mg cm−2
Rat/10.40±
0.34 mg cm−2
Skin excess(µgc m −2) 576.89 ± 35.54 590.73 ± 32.08
% applieddose 97.80 ± 1.38 92.07 ± 3.03
Stratum corneum (SC)
(µgc m −2)
<LOQ <LOQ
% applieddose <LOQ <LOQ
Epidermis + dermis (ED)
(µgc m −2)
0.03 ± 0.03 1.30 ± 1.18
% applieddose 0.005 ± 0.005 0.20 ± 0.18
Receptor ﬂuid (RF)
(µgc m −2)
1.163 ± 0.117 0.682 ± 0.453
% applieddose 0.03 ± 0.02 0.106 ± 0.067
Dermal delivery (ED+RF)
(µgc m −2)
0.193 ± 0.143 1.983 ± 1.616
% applieddose 0.03 ± 0.02 0.31 ± 0.24
Total recovery (%
applied dose)
97.83 ± 1.40 92.43 ± 2.97
studies and the 21 day study. It is probable that this resulted from
more thorough decontamination in the 21 day study.
3.5 Dermalabsorption of carbofuran
3.5.1 MeasurementofdermalabsorptionofcarbofuraninFuradan
5Gusinghumanandratskininvitro
At a dose of 9.56 mg cm−2, the dermal absorption of carbofuran
was 0.03 ± 0.02% for human skin over 24 h, including an 8 h
exposure period (Table 4).13 This had all penetrated the skin into
the receptor ﬂuid, and very little was associated with the dermal
residues. Using rat skin, the corresponding absorption ﬁgure, at a
dose of 10.40 mg cm−2,w a s0 .31 ± 0.24%, of which 34% of the
carbofuran was associated with the receptor ﬂuid and 65% with
the skin. The amount of carbofuran associated with the outer skin
layer, the stratum corneum, was below the limit of quantiﬁcation.
Although a positive control was not performed in this study,
the total recovery (97.83% for human and 92.43% for rat) was
acceptable, according to OECDguidelines(number 428). It can be
concludedthatabsorptionofcarbofuranfromFuradan 5Gbyrat
Figure 5. Percutaneous absorption of [14C]-carbofuran in Furadan 4F
and [14C]-piperonyl butoxide (PBO, 97 µgc m −2) applied to viable excised
human versus rat skin (mean ± SD, n = 6). Stratacor I: dermal absorption
(tape strips + epidermis + dermis + receptor ﬂuid); Stratacor II: dermal
penetration (dermis + receptor ﬂuid).10.
skin was approximately tenfold greater than for human skin. The
study was considered to provide complementary information to
that in the EU review by Belgium.15
3.5.2 Measurement of dermal absorption of [14C]-carbofuran in
Furadan 4Fusinghumanandratskininvitro
At doses of 5400 and 6100µg[ 14C]-carbofuran cm−2,v a l u e sf o r
dermal absorption through human skin were 0.64 ± 0.34% and
0.60 ± 0.11% respectively (n = 6d o s e −1).14 For rat skin at 4700
and6100 µg[ 14C]-carbofuran0.8 cm−2,thecorrespondingdermal
absorption values were 6.2 ± 2.6% and 8.4 ± 4.6%. As a positive
control,[14C]-piperonylbutoxideabsorption(at100µgc m −2)was
also measured in both systems. Values of 24 ± 3% (human)
and 52 ± 5% (rat), using n = 6d o s e −1, were obtained. These
human absorption values were above those reported in the
literature, ensuring that carbofuran dermal absorption was not
underestimated. All of the above calculations were based on
radiolabel recovered in receptor ﬂuid, dermis, epidermis and tape
strips 24 h after dosing the skin. The results (Fig. 5) indicate that
dermalabsorptionofcarbofuranbyratskinis9.7–14.0-foldgreater
thanbyhumanskin.Usingalessconservativecalculationofdermal
absorption,i.e.combiningreceptorﬂuidanddermis,thedifference
between rat and human skin was less, 4.4–5.9-fold, with rat again
absorbing more than human skin.
3.6 Calculations of occupational exposure
TheestimatesofoccupationalexposurearesummarizedinTable 5
(3G) and Table 6 (4F). For 3G application, rice was the crop chosen
forexposureassessment,whereas,for4F,estimatesincludedermal
exposure for several tasks on ten different crops. These are canola
(rapeseed), sunﬂower, corn, mustard, greenpepper, potato, sugar
beet, raspberry, strawberry and turnip.
3.7 Risk assessmentfor occupational exposure
The dermal toxicity endpoint (i.e. BMDL10 = 6.7m gk g −1 day−1)
used in this assessment was derived from an overall evaluation of
three acute dermal toxicity studies.7–9 In a 21 day dermal toxicity
study in rats, a BMDL10 of 6.8 mg kg−1 day−1 was determined.10
The dermal toxicity studies were considered to be appropriate for
derivation of a toxicity endpoint for the short- and intermediate-
term dermal exposures because the study was route speciﬁc. No
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Table 5. Occupational exposure/risk(MOE) for tasks associated with Furadan 3G applicationsto rice, using a single layer with no glovesa
Crop Application scenariob
Application
ratec (g AI ha−1)
Area treated
(ha day−1)
Dermal exposured
(µgk gd a y −1)M O E e
Rice ‘Push-type’granular spreader(open
pour) – M/L/A
1875 2 342.50 196
Rice Solid broadcast spreader, open cab, Ag
uses – open M/L
1875 80 39.68 1688
Rice Solid broadcast spreader, open cab, Ag
uses – A
1875 80 46.77 1433
a Mixer/loader: an open mixing and loading system.Applicator: a single layer (long-sleevedshirt and long trousers) with no gloves.
b M/L/A= Mixer/loader/applicator;M/L = mixer/loader;A = applicator.
c Maximum listed label application rate in g AI ha−1.
d Dermal exposure = (unit exposure × area treated × applicationrate) 70 kg−1.
e Based on a dermal BMDL10 of 67.0 mg kg−1 day−1 = 6.7m gk g −1 day−1 × 10 (relativerat/human dermal penetrationfactorfor Furadan 5G and a
target MOE = 100).
Table 6. Occupational exposure/risk (MOE) for tasks associated with Furadan 4F applications to ten crops, using maximum personal protection
equipmenta
Crops
Application
scenariob
Application ratec
(g AI ha−1)
Area treated
(ha day−1)
Dermal exposured
(µgk g −1 day−1)M O E e
Canola (rapeseed) Aerial – M/L 132 400 17.13 3795
Canola (rapeseed) Aerial – A 132 400 7.29 8916
Canola (rapeseed) Groundboom 132 100 0.16 411459
Sunﬂower Groundboom 132 100 0.16 411459
Corn Aerial – M/L 528 400 68.51 949
Corn Aerial – A 528 400 29.15 2230
Corn Groundboom 528 80 0.51 128581
Mustard Aerial – M/L 132 400 17.13 3795
Mustard Aerial – A 132 400 7.29 8916
Mustard Groundboom 132 100 0.16 411459
Green pepper Groundboom 528 30 0.19 342883
Potato Groundboom 528 80 0.51 128581
Sugar beet Groundboom 1123 30 0.40 161213
Raspberry Groundboom 1200 30 0.43 150868
Strawberry Groundboom 1200 30 0.43 150868
Rutabaga, turnip Groundboom 2520 60 1.81 35921
a Mixer/loader.An open mixingand loading systemwith chemical-resistantcoverallsovera single layerwith chemical-resistantgloves and a suitable
respirator. Groundboom applicator: a closed cab with chemical-resistant coveralls over a single layer (no gloves or respirators). Aerial applicator: a
single layer (long-sleevedshirt and long trousers), no gloves or respirators.
b M/L = mixer/loader;A = applicator; groundboom – farmer groundboom application.
c Maximum listed label application rate in g AI ha−1.
d Dermal exposure = (unit exposure × area treated × rate) 70 kg−1.
e Based on a dermal BMDL10 of 65.0 mg kg−1 = 6.7m gk g −1 day−1 × 9.7 (relative rat/human dermal penetrationfactor) and a target MOE of 100.
route-speciﬁc absorption factor adjustment was required in this
case because the risks from dermal exposure were assessed on
the basis of a toxicity endpoint from a dermal toxicity study.
However, the carbofuran invitro comparative rat versus human
dermalabsorptionstudiesshowedthathumanskinhascatenfold
(5G) and 9.7–14.0-fold (4F) less dermal absorption of carbofuran
in Furadan compared with rat skin,13,14 and these species
differences have been incorporated into this assessment.
The short- and intermediate-term MOEs for mixing, loading
and applying product in each typical exposure scenario were
considered for Furadan 3G and 4F label crop uses. The MOEs
estimatedfromdermalexposurearesummarizedinTables 5and 6
(including a 9.7× relative rat versus human dermal absorption
factor).
MOEs that are >100 indicate a margin of safety greater than
the level of concern, and those tasks are thus considered to
be acceptable and not hazardous for workers. For 3G uses
on rice, the calculated MOEs for mixing/loading and applying
carbofuran were above 100, even without wearing gloves. For
proposed uses of Furadan 4F, 15 of 16 exposure scenarios had
MOEs that were >100, without adjusting for human/rat dermal
absorption, so label uses of the product under these scenarios
are considered to pose no unacceptable risks to workers while
mixing, loading and applying the product. There was only one
scenario (mixing/loading for aerial application to corn) that had
an MOE of <100, suggesting that further reﬁnement was needed
for this use scenario. The additional reﬁnementof the 9.7-foldless
relative dermal absorption in human versus rat skin results in the
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calculated MOE at 949 for the scenario of corn mixing/loading
aerial.Therefore,alloftheexposurescenariosareconsideredtobe
safeforworkerswhenthehumandermalabsorptionfactorisused.
4 DISCUSSION
After dermal administration of carbofuran technical to the rat,
inhibition of brain and RBC AChE was recorded in the absence
of clinical signs of toxicity. The time of onset was rapid, with
signiﬁcant AChE inhibition being observed within 30 min of the
commencement of dosing. This onset time is similar to that
of carbofuran following oral gavage dosing of the rat.16 At
75 mg kg−1 day−1, the peak effect appeared to occur between
6 and 12 h after dermal dosing, slightly longer than after oral
gavage dosing.16 The relative inhibition of brain and RBC AChE
was similar after dermal and oral dosing, but, in the case of acute
dermal exposure, the brain enzyme was generally inhibited to
a greater degree than the RBC AChE. After a 6 h exposure, the
BMDL10 was 6.7 mg kg−1 day−1 for brain AChE, and this value
was chosen for conducting risk assessments for dermal exposure.
RecoveryofAChEactivityaftera6 hexposure waspartialforbrain
andcompleteforRBCby48–72 h.Becauseofresidualinhibitionof
brain AChE at 24 h, a 21 day repeat dose study was conducted for
betterdescriptionoftheeffectsofrepeatedexposure.Inthisstudy,
whichinvolveddoublewashingaftereachday’sexposure,slightly
greater inhibition of RBC AChE was observed, compared with the
brain enzyme, and a BMDL10 of 6.8 mg kg−1 day−1 was obtained
forbrain.ItwasconcludedthatthepoorrecoveryofbrainAChEin
the acute experiments resulted from incomplete washing of the
skin, such that dermal deposits acted as a reservoir of carbofuran
during the recovery phases. This conclusion is supported by two
earlier range-ﬁnding studies in which groups of rats were dosed
dermally for up to 6 h at 250 or 500 mg kg−1 day−1,17 and at
750 mg kg−1 day−1,18 followedbymeasurementofbrainandRBC
AChE inhibition 3, 6, 6.5, 7, 8, 9 and 25 h after the start of dosing.
The inhibition of AChE (brain and RBC) was between 50 and
63% for all (three) doses at all time points. The interpretation of
these data was that, because dermal absorption usually declined
(as a percentage of applied dose) as the dose increased, it is
probable that the internal dose, as well as the AChE inhibition,
was the same at the three dosages. In all of these studies, the only
rats showing clinical signs of tremors, convulsions and salivation
were individuals that had removedtheir collarsand thus ingested
carbofuran orally.
At the enzyme level, recovery of brain AChE from carbofuran
inhibition is relatively rapid, as demonstrated by studies using
gavage dosing. For example, at 0.5 mg kg−1, inhibition of rat
brain AChE of ca 40% within 30–60 min of dosing had returned
to normal by 24 h.19 Brain and RBC AChE were inhibited to
similar degrees, with the latter inhibited slightly more than the
former. In an oral gavage dose response study, carbofuran at
0.1–1.5 mg kg−1 inhibited AChE to similar degrees, along with
causing corresponding depressions of motor activity.20 In a time-
coursestudyinimmaturerats,oralgavagedosingwithcarbofuran
resulted in peak inhibition of AChE at 15–45 min (brain) and
15–180 min (RBC), with complete recovery of both enzymes
by 24 h.16 Thus, although these studies demonstrated relatively
rapid reversal of AChE inhibition by carbofuran compared with
organophosphate inhibition, they all used oral gavage dosing,
giving little indication of the reversibility of carbofuran effects
afterdermalexposure.Thestudiesdescribedinthispapersuggest
that recovery of AChE following dermal exposure also occurs
within24 h,especiallywithadequatewashingaftereachexposure.
Extrapolatingtohumans,thisindicatesthatPPEandgoodhygiene
are important to worker safety.
Dermal absorption of carbofuran in Furadan 5G and 4F was
measured, invitro, using human and rat skin samples. The 5G
is anticipated to be similar to the 3G, which was used in the
occupational exposure calculations. The granular was absorbed
less than the liquid formulation by both rat and human skin.
Moreover, both formulations were absorbed more by rat than
by human skin (ca tenfold). Dermal penetration of 4F included
[14C]inreceptorﬂuidplusdermis,whereasabsorptionadditionally
included[14C]retainedintheepidermis.Penetrationofcarbofuran
through rat skin was 4–6-fold greater than through human skin.
The dermal absorption into skin was 9.7–14.0-fold greater in
rat than in human skin. In addition, absorption of the positive
control in these studies ([14C]-piperonyl butoxide) was greater
than in literature reports, assuring that dermal absorption of
[14C]-carbofuran was unlikely to be underestimated. EPA and
other regulatory bodies have consistently taken into account the
rat/human relative dermal penetration/absorption of a pesticide
when conducting a risk assessment. For carbaryl,21 an invitro
dermal penetration factor of 2.8-fold was applied to the critical
ratdermalBMDL10 followinganinvitrocomparative dermalstudy
similar to the one described here for carbofuran.
The3GgranularformulationofcarbofurangaveadequateMOEs
(>100) for all tasks (M/L/A) in applications on rice, even without
the most basic PPE, i.e. no gloves. Because rice is a crop on which
carbofuran is used heavily, it is therefore anticipated that other
crops will also have adequate MOEs. The use of the liquid 4F
formulation, however, required maximum PPE for open cab and
open system tasks, including a respirator, and gave lower MOEs
than the use of 3G granular material, with minimal PPE. MOEs for
4Fwerenonethelessabove100evenwithoutadjustingforrelative
rat/human dermal absorption in 15 of 16 scenarios. By including
this factor, all of the scenarios had adequate MOEs.
5C O N C L U S I O N S
The dermal toxicity of carbofuran in relation to the risk of
agricultural worker illness incidents was determined in this paper
through a series of toxicity and dermal absorption studies. The rat
was used to determine the time of onset, time to peak effect and
timetorecoveryofbrainAChEactivity,usingcarbofurantechnical.
Using 75 mg kg−1 day−1 (giving ≥20% inhibition of both brain
andRBC AChE), it wasfoundthat time of onsetwaswithin 30 min,
time to peak effect was approximately 6 h and recovery of brain
AChE activity was incomplete, even at 72 h. In a 21 day repeat-
dose dermal study there was no evidence of increased toxicity,
so recovery within 24 h was indicated. BMDL10 values of 6.7 and
6.8 mg kg−1 day−1 were obtained for brain AChE inhibition in
acute (6 h) and 21 day studies respectively. Rat skin was found to
be ca tenfold more permeable to carbofuran than human skin.
Using PHED and AHED, granular carbofuran (Furadan 3G) use
on rice had MOE values above 100, even without wearing gloves,
whereas, for Furadan 4F, full PPE was required before the MOE
was above 100. For this reason, liquid formulations of Furadan
are used only under controlled conditions.
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